CDK4 and Thromboembolism: Based on the FAERS, previous pharmacovigilance studies have elucidated the relationship between CDK4/6i and several AEs, including thromboembolism,29 hematopoietic cytopenia,30 skin toxicities31 and interstitial lung disease.32